Drugs / NARNATUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01119456 | May 2010 → Nov 2013 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NARNATUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743046 ↗ |
| Known as | IMC-RON8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119456 ↗ |
| Known as | RON-8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743046 ↗ |
| Action | Inhibit | “Macrophage-stimulating protein receptor inhibitor” CHEMBL1743046 ↗ |
| Modality | Monoclonal antibody | “A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).” NCT01119456 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT01119456 ↗ |
| Target | MST1R | “Macrophage-stimulating protein receptor inhibitor” CHEMBL1743046 ↗ |